<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Fostering</title>
	<atom:link href="http://www.tapanray.in/tag/fostering/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>&#8216;Big Pharma&#8217; Prowls Falter: Triggers Off Yet Another Critical Debate</title>
		<link>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-prowls-falter-triggers-off-yet-another-critical-debate</link>
		<comments>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/#comments</comments>
		<pubDate>Mon, 25 Nov 2013 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[council. India]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fostering]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[off]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pitroda]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Professor]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sam]]></category>
		<category><![CDATA[SME]]></category>
		<category><![CDATA[sparks]]></category>
		<category><![CDATA[stricter]]></category>
		<category><![CDATA[stumbles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[triggers]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Wharton]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3101</guid>
		<description><![CDATA[The &#8216;Big Pharma&#8217; prowls faltered yet again exposing the ‘fault line’ to all, when the GSK global head honcho, a pharma icon in his own right, Sir Andrew Witty supported the pharmaceutical policy of India, while in the country earlier &#8230; <a href="http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fostering ‘Innovation’ and protecting of ‘Public Health Interest’: A formidable task for the new TF (taskforce)</title>
		<link>http://www.tapanray.in/fostering-innovation-and-protecting-of-public-health-interest-a-formidable-task-for-the-new-tf-taskforce/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fostering-innovation-and-protecting-of-public-health-interest-a-formidable-task-for-the-new-tf-taskforce</link>
		<comments>http://www.tapanray.in/fostering-innovation-and-protecting-of-public-health-interest-a-formidable-task-for-the-new-tf-taskforce/#comments</comments>
		<pubDate>Mon, 28 Mar 2011 00:30:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and. protecting]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[formidable]]></category>
		<category><![CDATA[Fostering]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Minidtry]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[task]]></category>
		<category><![CDATA[Taskforce]]></category>
		<category><![CDATA[TF]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=284</guid>
		<description><![CDATA[‘The Lancet’, March 19, 2011 in its article titled “India: access to affordable drugs and the right to health”, where the authors reiterated: ‘The right to health is a fundamental right in India, judicially recognized under article 21 of the &#8230; <a href="http://www.tapanray.in/fostering-innovation-and-protecting-of-public-health-interest-a-formidable-task-for-the-new-tf-taskforce/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fostering-innovation-and-protecting-of-public-health-interest-a-formidable-task-for-the-new-tf-taskforce/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
